EP2358866A2 - A corynebacteria strain having enhanced 5'-xanthosine monophosphate productivity and a method of producing 5'-xanthosine monophosphate using the same - Google Patents

A corynebacteria strain having enhanced 5'-xanthosine monophosphate productivity and a method of producing 5'-xanthosine monophosphate using the same

Info

Publication number
EP2358866A2
EP2358866A2 EP09833645A EP09833645A EP2358866A2 EP 2358866 A2 EP2358866 A2 EP 2358866A2 EP 09833645 A EP09833645 A EP 09833645A EP 09833645 A EP09833645 A EP 09833645A EP 2358866 A2 EP2358866 A2 EP 2358866A2
Authority
EP
European Patent Office
Prior art keywords
strain
corynebacteria
mqo
xmp
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09833645A
Other languages
German (de)
French (fr)
Other versions
EP2358866B1 (en
EP2358866A4 (en
Inventor
Jinman Cho
Hye Won Kim
Jinnam Lee
Ji-Hye Lee
Yoon Seok Oh
Jang Hee Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ CheilJedang Corp
Original Assignee
CJ CheilJedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ CheilJedang Corp filed Critical CJ CheilJedang Corp
Publication of EP2358866A2 publication Critical patent/EP2358866A2/en
Publication of EP2358866A4 publication Critical patent/EP2358866A4/en
Application granted granted Critical
Publication of EP2358866B1 publication Critical patent/EP2358866B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/02Monosaccharides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/32Nucleotides having a condensed ring system containing a six-membered ring having two N-atoms in the same ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Definitions

  • the present invention relates to a recombinant vector, having the structure shown in the cleavage map of FIG. 1 which carries a gene of SEQ ID NO. 7 and a Corynebacteria strain, transformed with the recombinant vector, having higher than the endogenous malate dehydrogenase activity. Also, the present invention is concerned with a method of producing 5'-xanthosine monophosphate using the Corynebacteria strain.
  • GMP 5'-Guanosine monophosphate
  • IMP inosine monophosphate
  • MSG monosodium glutamate
  • Examples of the methods for the preparation of GMP known thus far include (1) the enzymatic degradation of yeast RNA, (2) direct microorganism fermentation to GMP,
  • microorganism fermentation to xanthosine 5 '-monophosphate hereinafter referred to as "XMP"
  • XMP xanthosine 5 '-monophosphate
  • method (1) has difficulties of material supply and is economically non-beneficial and method (2) suffers from the disadvantage of being of low yield due to the membrane permeability of GMP.
  • the other methods are widely used in industrial applications.
  • Korean Patent Application No. 10-1991-018016 discloses an XMP aminase-inactive strain capable of producing XMP in high yield, which is semi-auxotrophic for adenine and guanine, tolerant of guanosine analoges and very susceptible to lysozyme, an enzyme which destroying cell walls.
  • Korean Patent Application No. 10-2001-000513 discloses a strain of Corynebacterium ammoniagenes which can directly accumulate XMP at high concentration in a culture medium and a method of producing XMP using the same.
  • the strain is prepared by irradiating the mother microorganism with UV light, treating with the mutagen N- methyl-N'-nitro-N-nitrosoguanidine (NTG), and selecting a mutant tolerant of norvaline, an analog of valine which affects the biosynthesis of XMP.
  • NMG mutagen N- methyl-N'-nitro-N-nitrosoguanidine
  • Korean Patent Application No. 10-2008-006537 describes a method of increasing XMP yield in which purN and purH, genes involved in the biosynthesis of XMP, are modified.
  • XMP-producing strain the present inventors conducted intensive research and found a gene which is responsible for the increase. Also, it was found that a Corynebacteria strain transformed with a recombinant vector carrying two copies of the gene in tandem, could produce XMP in high yield.
  • the present invention is directed to a corynebacteria strain with enhancements over endogenous malate dehydrogenase activity.
  • the corynebacteria strain of the present invention is modified to have malate dehydrogenase activity higher than endogenous activity, resulting in an enhancement in XMP productivity.
  • malate dehydrogenase means an enzyme that catalyzes the conversion of malate into oxaloacetate by dehydrogenation. This enzyme is found in a very broad spectrum of living organisms with the accompaniment of lactate dehydrogenase and requires DPN and NAD as cofactors for its activity, these usually accompanying lactate dehydrogenase. In the corynebacteria strain according to the present invention, the malate dehydrogenase activity is increased to produce XMP in higher yield.
  • endogenous activity is intended to refer to the enzyme activity of interest in a wild-type microorganism.
  • higher than endogenous activity means increased enzyme activity compared to the activity of the endogenous variety, whether resulting from an activity increase by the enzyme itself or by an endogenous gene or a foreign gene.
  • an increase in enzyme activity may be achieved by any method well known in the art, including, but not limited to, increasing or decreasing the number of gene copies, replacing, modifying or mutating a promoter of interest, etc.
  • the target enzyme malate dehydrogenase whose activity is sought to be increased according to the present invention is encoded by the mqo gene of Corynebacteria.
  • any derivative or analog may be used in the present invention. That is, if its activity is substantially the same as or similar to that of the mqo gene, any gene falling within the range of the mqo gene is useful in the present invention.
  • the gene useful in the present invention shares at least 70%, more preferably at least 80%, even more preferably at least 90%, even far more preferably at least 95% and most preferably at least 98% homology with the sequence of the mqo gene.
  • the malate dehydrogenase is encoded by the nucleotide sequence of SEQ ID NO.: 7.
  • the increase of gene copies can be achieved by the introduction of exogenous genes and/or the amplification of endogenous genes. The number of gene copies may be readily determined by those skilled in the art according to need and purpose.
  • the amplification of the endogenous gene can also be conducted using a method known in the art, for example, by culturing in a suitable selective medium under pressure.
  • a vector carrying a gene coding for malate dehydrogenase is introduced into a corynebacteria strain to generate a transformed microorganism with an enhancement over the endogenous activity.
  • any strain may be used in the present invention without limitation.
  • examples of the corynebacteria strain useful in the present invention include Corynebacterium ammo- niagenes, Corynebacterium glutamicum, Brevibacterium flavum, and Brevibacterium lactofermentum, but are not limited thereto.
  • Corynebacteria strains are Corynebacterium ammoniagenes ATCC6872, Corynebacterium thermoaminogenes FERM BP- 1539, Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum R, Brevibacterium flavum ATCC 14067, Brevibacterium lactofermentum ATCC 13869 and derivatives thereof.
  • Preferred is Corynebacterium ammoniagenes KCJ-1304 transformed from Corynebacterium ammoniagenes KCCM-10530.
  • the present invention is directed into a recombinant vector having the structure shown in the cleavage map of FIG. 1, which carries the gene of SEQ ID NO. 7.
  • the gene of SEQ ID NO. 7 has a wild-type nucleotide sequence of an mqo gene from
  • mqo gene an abbreviation of "malate:quinone oxidoreductase” gene, means a gene coding for malate oxaloacetate which functions to oxidize malate to oxaloacetate.
  • the present invention provides a recombinant vector carrying the mqo gene of SEQ ID NO. 7.
  • any usual recombinant vector can be employed in the present invention without limitation.
  • Preferable is pDZ-mqo.
  • the mqo gene containing SEQ ID NO. 7 was employed to construct a recombinant pDZ-mqo vector (see FIG. 1).
  • the present invention is directed to a
  • Corynebacteria strain transformed with a recombinant vector carrying the mqo gene transformed with a recombinant vector carrying the mqo gene.
  • the corynebacteria-derived mqo gene may be used using a transformation method known in the art without limitation.
  • the mqo gene is cloned in a vector for use in transformation into cells.
  • transformation is the genetic alteration of a cell resulting from the uptake, genomic incorporation and expression of foreign DNA.
  • Typical transformation methods include CaCl 2 precipitation, a Hanahan method in which the effect of CaCl 2 precipitation is improved in combination with DMSO (dimethyl sulfoxide), electro- poration, calcium phosphate transfection, protoplast fusion, silicon carbide fiber- mediated transformation, agrobacterium-mediated transformation, PEG-mediated transformation, dextran sulfate, lipofectamine, and desiccation/inhibition-mediated transformation. Transformation with pDZ-mqo in accordance with the present invention is not limited to the examples of transformation, but can be achieved using any method known in the art without limitation.
  • vector means a DNA molecule used as a vehicle to transfer foreign genetic material into a suitable host cell and is a DNA construct containing regulatory elements which allow a transgene to do recombination with a host genome.
  • the recombinant vector carrying the mqo vector in accordance the present invention may have the structure shown in the cleavage map of FIG. 1.
  • the vector represented by the cleavage map of FIG. 1 may be introduced into corynebacteria sequentially or simultaneously.
  • the recombinant vector is transformed into Corynebacterium ammoniagenes KCCM- 10530 which is then cultured in a selective medium to allow two copies of the mqo gene to incorporate into the genome of the host through homologous recombination, resulting in the generation of a Corynebacterium ammoniagenes mutant, named Corynebacterium ammoniagenes KCJ- 1304. It was deposited with accession number KCCM10972P.
  • Corynebacterium ammoniagenes KCJ- 1304 has two copies of mqo gene incorporated into the genome of KCCM- 10530 resulting from the introduction thereinto of pDZ- mqo having the structure shown in the cleavage map of FIG. 1 and the homologous recombination of two copies of mqo gene with the endogenous gene.
  • the present invention is directed to a method of producing XMP, comprising: culturing the transformed corynebacteria strain and obtaining XMP from the culture.
  • XMP is produced in higher yield by the direct fermentation of the transformed microorganism.
  • the transformed microorganism is the corynebacteria strain which is enhanced in malate dehydrogenase activity over the endogenous activity.
  • the mqo gene of the recombinant vector is preferably incorporated into the genome of the transformed microorganism which can thus produce XMP in high yield.
  • the microorganism is Corynebacterium ammoniagenes KCCM10972P.
  • any medium known in the art may be used without limitation in culturing the strain capable of producing XMP.
  • the medium contains glucose as a carbon source and optionally various other carbon sources.
  • a medium For use in culturing a microorganism of interest, a medium must meet requirements for the growth of the microorganism.
  • Culture media for corynebacteria strains are known in the art (e.g., Manual of Methods for General Bacteriology. American Society for Bacteriology. Washington D. C, USA, 1981).
  • Examples of the carbon sources useful for corynebacteria strains include sugars and carbohydrates such as glucose, saccharose, lactose, fructose, maltose, starch, cellulose, etc., oils and lipids such as soybean oil, sunflower oil, castor oil, coconut oil, etc., fatty acids such as palmitic acid, stearic acid, linolenic acid, etc., alcohols such as glycerol, ethanol, etc., and organic acids such as acetic acid. These carbon sources may be used individually or in combination.
  • Organic materials such as peptone, yeast extract, beef extract, malt extract, corn steep liquor, soybean, etc., urea, and inorganic compounds such as ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate may be used individually or in combination as nitrogen sources in the medium. Potassium dihydrogen phosphate or dipotassium hydrogen phosphate, or corresponding sodium salts may be useful as phosphorus sources.
  • the culture medium may contain metal salts such as magnesium sulfate, iron sulfate, etc. Further, amino acids and/or vitamins may be required as essential elements.
  • the culture medium may also contain suitable precursors. These materials may be added to a medium in a batch manner or continuous manner.
  • the culture medium may be adjusted in pH by basic compounds such as sodium hydroxide, potassium hydroxide, ammonia, etc. or acid compounds such as phosphoric acid or sulfuric acid.
  • An antifoaming agent such as fatty acid polyglycol ester may be used to prevent the generation of bubbles during the culturing.
  • the medium may be aerated with oxygen or oxygen-containing gas (e.g., air) to maintain an aerobic condition or with nitrogen, hydrogen or carbon dioxide gas to maintain an anaerobic condition.
  • Culturing temperature is usually maintained at 2O 0 C ⁇ 45 0 C, and preferably at 3O 0 C ⁇ 35 0 C. Culturing is continued until the maximum amount of XMP is obtained. In this regard, a time period of from 10 to 160 hours is required.
  • the 5XMP thus produced may be secreted into the culture medium or remain within the cell.
  • the method of producing XMP in accordance with the present invention comprises recovering XMP from the cells or the culture medium.
  • any method well known in the art may be utilized. Examples of such methods include filtration, anionic exchange chromatography, crystallization, and HPLC, but are not limited thereto.
  • the term "5'-xanthosine monophosphate” is an intermediate in nucleic acid biosynthesis and is of physiological significance in animals and plants. Thus, it finds applications in a variety of fields including the food industry, the pharmaceutical industry and the medical industry.
  • Xanthosine monophosphate are food additives used as nucleic acid-based flavor enhancers to provide the taste of mushroom particularly in synergy with MSG.
  • XMP is an intermediate in purine metabolism, formed from IMP, forming GMP. When using the transformed microorganism in accordance with the present invention, XMP can be produced in a high yield which is found to be improved by about 6% compared to conventional microorganisms.
  • the transformed corynebacteria strain of the present invention produces XMP in higher yield than do conventional microorganisms.
  • FIG. 1 is a schematic diagram showing the structure of the recombinant vector pDZ- mqo in which two copies of an mqo gene are inserted into a pDZ vector.
  • EXAMPLE 1 Cloning of the XMP-Producing Strain Corynebacterium ammo- niagenes KCCM- 10530-Derived mqo and Construction of Recombinant Vector (pDZ-mqo) for Genomic Incorporation
  • nucleotide sequence of the mqo gene (NCBI ID_3345228) was obtained from data from the NIH GenBank. Based on the sequence, two pairs of primers (SEQ ID NOS. 1 to 4) were synthesized.
  • PCR was conducted in the presence of the high-fidelity DNA polymerase PfuUltraTM (Stratagene) using the primers of SEQ ID NOS. 1 to 4, with 25 cycles of denaturing at 95 0 C for 30 sec, annealing at 55 0 C for 30 sec and extension at 68 0 C for 2 min.
  • the PCR products thus obtained were two copies of the mqo gene, each 2.1 kb long (mqo-A, mqo-B), which were amplified using two sets of SEQ ID NOS: 1 and 2, and SEQ ID NOS: 3 and 4, respectively.
  • FIG. 1 is a schematic diagram showing the structure of the recombinant pDZ-mqo vector for incorporation into Corynebacterium genome.
  • the pDZ-mqo vector construct was transformed into the KCCM- 10530 strain and subjected to homologous recombination with the genome to insert one mqo gene copy at a position adjacent to the mqo gene on the genome.
  • a novel XMP-producing strain named Corynebacterium ammoniagenes KCJ- 1304, which had two copies of the mqo gene on the genome thereof, was obtained.
  • the insertion of two copies of the mqo gene in tandem was identified using PCR using a set of primers (SEQ ID NOS. 5 and 6) which targeted nucleotide sequences upstream and downstream of the two copies of the mqo gene.
  • SEQ ID NO. 6 CCACTTTATCGGGTGAGACCA
  • Example 2 was assayed for malate dehydrogenase activity as follows. The strain was inoculated into a medium containing 10g/f bactopeptone, 5gll bacto-beef extract, 5gll bacto-yeast extract, 2.5gll NaCl, 50 mg/f adenine, and 50 mg/f guanine and incubated at 3O 0 C for 12 hrs until OD 10 was obtained. 10 mL of the cell culture was recovered, washed twice with buffer comprising 50 mM HEPES, 1OmM potassium acetate, 1OmM CaCl 2 and 1OmM MgCl 2 , and suspended in 1 mL of the same buffer.
  • buffer comprising 50 mM HEPES, 1OmM potassium acetate, 1OmM CaCl 2 and 1OmM MgCl 2 , and suspended in 1 mL of the same buffer.
  • reaction buffer was prepared by mixing 5OmM HEPES, 1OmM potassium acetate and 50 ⁇ M 2,6-dichloroindolphenol (C12Ind). C12Ind was thawed and mixed just before reaction. To 980 ⁇ L of the reaction mixture were added 10 ⁇ L of 100 mM malate as a substrate and 10 ⁇ L of the enzyme solution, followed by incubation at 3O 0 C for 15 min with shaking. The enzyme activity was determined by measuring the concentration of reduced Cl 2 lnd. Cl 2 lnd had an absorption coefficient of 22 cm- ImM-I at 600 nm.
  • KCJ- 1304 was observed to increase in malate dehydrogenase activity by 30.6% compared to the mother strain KCCM- 10530.
  • Example 2 was cultured to produce XMP as follows.
  • the mother strain Corynebacterium ammoniagenes KCCM-10530 and the mutant KCJ-1304 were inoculated into respective 14 mL tubes, each containing 3 mL of the following seed medium, and incubated at 3O 0 C for 20 hrs with shaking at 200 rpm.
  • the seed cultures were added in an amount of 0.4 mL to 32 mL of the following production medium (24 mL of main medium + 8 mL of medium A) in respective 250 mL corner- baffle flasks, followed by shake culturing at 3O 0 C and 230 rpm for 96 hrs. Thereafter, the production of 5'-XMP was quantitatively measured using HPLC.
  • the XMP amounts produced from Corynebacterium ammogenes KCCM-10530 and KCJ-1304 are given in Table 2, below.
  • Seed Medium glucose 30g/f, peptone 15g/f, yeast extract 15g/f, NaCl 2.5g/£, urea 3g/f, adenine 150 mg/f, guanine 150 mg/f, pH 7.2
  • Production Medium glucose 80g/f, magnesium sulfate 10g/f , ferrous sulfate 20 mg/f, zinc sulfate 10 mg/f , manganese sulfate 10 mg/f, adenine 30 mg/f , guanine 30 mg/f, biotin 100 ⁇ glt, copper sulfate 1 mg/f, thiamine chloride 5 mg/f , calcium chloride 10 mg/£ pH 7.2

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Disclosed is a novel microorganism which has a malate dehydrogenase activity higher than that of a wild-type. Also, a recombinant vector which has the structure shown in the cleavage map of FIG. 1, a Corynebacteria strain transformed therewith, and a method of producing 5'-xanthosine monophosphate by culturing the transformed strain are disclosed.

Description

    A CORYNEBACTERIA STRAIN HAVING ENHANCED 5’-XANTHOSINE MONOPHOSPHATE PRODUCTIVITY AND A METHOD OF PRODUCING 5’-XANTHOSINE MONOPHOSPHATE USING THE SAME
  • The present invention relates to a recombinant vector, having the structure shown in the cleavage map of FIG. 1 which carries a gene of SEQ ID NO. 7 and a Corynebacteria strain, transformed with the recombinant vector, having higher than the endogenous malate dehydrogenase activity. Also, the present invention is concerned with a method of producing 5’-xanthosine monophosphate using the Corynebacteria strain.
  • 5’-Guanosine monophosphate (hereinafter referred to as “GMP”) is a food additive widely used as a flavor enhancer, like inosine monophosphate (hereinafter referred to as “IMP”). GMP elicits an umami taste and its use is dependent on monosodium glutamate (MSG) also being used. It is often used in synergy with IMP to increase the intensity of the umami taste of MSG.
  • Examples of the methods for the preparation of GMP known thus far include (1) the enzymatic degradation of yeast RNA, (2) direct microorganism fermentation to GMP, (3) microorganism fermentation to guanosine, followed by chemical phosphorylation, (4) microorganism fermentation to guanosine, followed by enzymatic phosphorylation, (5) microorganism fermentation to xanthosine 5’-monophosphate (hereinafter referred to as “XMP”), followed by conversion into GMP by a corynebacteria strain, and (6) microorganism fermentation to XMP, followed by conversion of XMP into GMP by Escherichia coli which has aminase activity. Of them, method (1) has difficulties of material supply and is economically non-beneficial and method (2) suffers from the disadvantage of being of low yield due to the membrane permeability of GMP. Thus, the other methods are widely used in industrial applications.
  • For the method in which XMP is produced and converted into GMP, it is critical to increase XMP productivity. For example, Korean Patent Application No. 10-1991-018016 discloses an XMP aminase-inactive strain capable of producing XMP in high yield, which is semi-auxotrophic for adenine and guanine, tolerant of guanosine analoges and very susceptible to lysozyme, an enzyme which destroying cell walls. Korean Patent Application No. 10-2001-000513 discloses a strain of Corynebacterium ammoniagenes which can directly accumulate XMP at high concentration in a culture medium and a method of producing XMP using the same. The strain is prepared by irradiating the mother microorganism with UV light, treating with the mutagen N-methyl-N’-nitro-N-nitrosoguanidine (NTG), and selecting a mutant tolerant of norvaline, an analog of valine which affects the biosynthesis of XMP. Korean Patent Application No. 10-2008-006537 describes a method of increasing XMP yield in which purN and purH, genes involved in the biosynthesis of XMP, are modified.
  • On the other hand, ATP productivity leads to XMP yield because ATP is involved in the biosynthesis of XMP. Also, The activity of malate dehydrogenase has a great influence on the production of ATP. However, nowhere are microorganisms and methods which are designed to enhance malate dehydrogenase activity for increasing XMP production yields mentioned in previous documents.
  • Keeping in the mind that it is important to increase the ATP productivity of the XMP-producing strain, the present inventors conducted intensive research and found a gene which is responsible for the increase. Also, it was found that a Corynebacteria strain transformed with a recombinant vector carrying two copies of the gene in tandem, could produce XMP in high yield.
  • It is therefore an object of the present invention to provide a Corynebacteria strain having higher than the endogenous malate dehydrogenase activity.
  • It is another object of the present invention to provide a recombinant vector having the structure shown in the cleavage map of FIG. 1 which carries the gene of SEQ ID NO. 7.
  • It is a further object of the present invention to provide a Corynebacteria strain transformed with the recombinant vector.
  • It is still a further object of the present invention to provide a method of producing XMP by culturing the transformed microorganism and obtaining XMP from the culture.
  • In accordance with an aspect thereof, the present invention is directed to a corynebacteria strain with enhancements over endogenous malate dehydrogenase activity. Preferably, the corynebacteria strain of the present invention is modified to have malate dehydrogenase activity higher than endogenous activity, resulting in an enhancement in XMP productivity.
  • The term “malate dehydrogenase”, as used herein, means an enzyme that catalyzes the conversion of malate into oxaloacetate by dehydrogenation. This enzyme is found in a very broad spectrum of living organisms with the accompaniment of lactate dehydrogenase and requires DPN and NAD as cofactors for its activity, these usually accompanying lactate dehydrogenase. In the corynebacteria strain according to the present invention, the malate dehydrogenase activity is increased to produce XMP in higher yield.
  • As used herein, the term “endogenous activity” is intended to refer to the enzyme activity of interest in a wild-type microorganism. The term “higher than endogenous activity” means increased enzyme activity compared to the activity of the endogenous variety, whether resulting from an activity increase by the enzyme itself or by an endogenous gene or a foreign gene. For example, an increase in enzyme activity may be achieved by any method well known in the art, including, but not limited to, increasing or decreasing the number of gene copies, replacing, modifying or mutating a promoter of interest, etc.
  • The target enzyme malate dehydrogenase whose activity is sought to be increased according to the present invention is encoded by the mqo gene of Corynebacteria. As long as it is biologically identical or correspondends to the mqo gene, any derivative or analog may be used in the present invention. That is, if its activity is substantially the same as or similar to that of the mqo gene, any gene falling within the range of the mqo gene is useful in the present invention. Advantageously, the gene useful in the present invention shares at least 70%, more preferably at least 80%, even more preferably at least 90%, even far more preferably at least 95% and most preferably at least 98% homology with the sequence of the mqo gene. More advantageously, the malate dehydrogenase is encoded by the nucleotide sequence of SEQ ID NO.: 7. The increase of gene copies can be achieved by the introduction of exogenous genes and/or the amplification of endogenous genes. The number of gene copies may be readily determined by those skilled in the art according to need and purpose. The amplification of the endogenous gene can also be conducted using a method known in the art, for example, by culturing in a suitable selective medium under pressure. In a preferred example, a vector carrying a gene coding for malate dehydrogenase is introduced into a corynebacteria strain to generate a transformed microorganism with an enhancement over the endogenous activity.
  • As long as it is known in the art and belongs to the corynebacteria genus, any strain may be used in the present invention without limitation. Preferably, examples of the corynebacteria strain useful in the present invention include Corynebacterium ammoniagenes, Corynebacterium glutamicum, Brevibacterium flavum, and Brevibacterium lactofermentum, but are not limited thereto. In detail, among the corynebacteria strains are Corynebacterium ammoniagenes ATCC6872, Corynebacterium thermoaminogenes FERM BP-1539, Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum R, Brevibacterium flavum ATCC 14067, Brevibacterium lactofermentum ATCC 13869 and derivatives thereof. Preferred is Corynebacterium ammoniagenes KCJ-1304 transformed from Corynebacterium ammoniagenes KCCM-10530.
  • In accordance with another aspect thereof, the present invention is directed into a recombinant vector having the structure shown in the cleavage map of FIG. 1, which carries the gene of SEQ ID NO. 7.
  • The gene of SEQ ID NO. 7 has a wild-type nucleotide sequence of an mqo gene from Corynebacteria. However, it is obvious that a recombinant vector which carries a derivative or analog of the mqo gene is also useful in the present invention as long as the derivative or analog is biologically identical or correspondends to the mqo gene, as mentioned above. As used herein, the term “mqo gene”, an abbreviation of “malate:quinone oxidoreductase” gene, means a gene coding for malate oxaloacetate which functions to oxidize malate to oxaloacetate.
  • In a preferred embodiment, the present invention provides a recombinant vector carrying the mqo gene of SEQ ID NO. 7. As long as it carries an mqo gene, any usual recombinant vector can be employed in the present invention without limitation. Preferable is pDZ-mqo. In a preferred example of the present invention, the mqo gene containing SEQ ID NO. 7 was employed to construct a recombinant pDZ-mqo vector (see FIG. 1).
  • In accordance with a further aspect thereof, the present invention is directed to a Corynebacteria strain transformed with a recombinant vector carrying the mqo gene.
  • The corynebacteria-derived mqo gene may be used using a transformation method known in the art without limitation. Preferably, the mqo gene is cloned in a vector for use in transformation into cells.
  • Any method may be employed for transformation if it is known in the art. As used herein, the term “transformation” is the genetic alteration of a cell resulting from the uptake, genomic incorporation and expression of foreign DNA. Typical transformation methods include CaCl2 precipitation, a Hanahan method in which the effect of CaCl2 precipitation is improved in combination with DMSO (dimethyl sulfoxide), electroporation, calcium phosphate transfection, protoplast fusion, silicon carbide fiber-mediated transformation, agrobacterium-mediated transformation, PEG-mediated transformation, dextran sulfate, lipofectamine, and desiccation/inhibition-mediated transformation. Transformation with pDZ-mqo in accordance with the present invention is not limited to the examples of transformation, but can be achieved using any method known in the art without limitation.
  • The term “vector”, as used herein, means a DNA molecule used as a vehicle to transfer foreign genetic material into a suitable host cell and is a DNA construct containing regulatory elements which allow a transgene to do recombination with a host genome. Preferably, the recombinant vector carrying the mqo vector in accordance the present invention may have the structure shown in the cleavage map of FIG. 1. The vector represented by the cleavage map of FIG. 1 may be introduced into corynebacteria sequentially or simultaneously. In accordance with a preferred embodiment of the present invention, the recombinant vector is transformed into Corynebacterium ammoniagenes KCCM-10530 which is then cultured in a selective medium to allow two copies of the mqo gene to incorporate into the genome of the host through homologous recombination, resulting in the generation of a Corynebacterium ammoniagenes mutant, named Corynebacterium ammoniagenes KCJ-1304. It was deposited with accession number KCCM10972P.
  • Corynebacterium ammoniagenes KCJ-1304 has two copies of mqo gene incorporated into the genome of KCCM-10530 resulting from the introduction thereinto of pDZ-mqo having the structure shown in the cleavage map of FIG. 1 and the homologous recombination of two copies of mqo gene with the endogenous gene.
  • In accordance with a further aspect thereof, the present invention is directed to a method of producing XMP, comprising: culturing the transformed corynebacteria strain and obtaining XMP from the culture. In the present invention, XMP is produced in higher yield by the direct fermentation of the transformed microorganism. Preferably, the transformed microorganism is the corynebacteria strain which is enhanced in malate dehydrogenase activity over the endogenous activity. The mqo gene of the recombinant vector is preferably incorporated into the genome of the transformed microorganism which can thus produce XMP in high yield. In a preferred embodiment, the microorganism is Corynebacterium ammoniagenes KCCM10972P.
  • Any medium known in the art may be used without limitation in culturing the strain capable of producing XMP. Preferably, the medium contains glucose as a carbon source and optionally various other carbon sources. For use in culturing a microorganism of interest, a medium must meet requirements for the growth of the microorganism. Culture media for corynebacteria strains are known in the art (e.g., Manual of Methods for General Bacteriology. American Society for Bacteriology. Washington D.C., USA, 1981). Examples of the carbon sources useful for corynebacteria strains include sugars and carbohydrates such as glucose, saccharose, lactose, fructose, maltose, starch, cellulose, etc., oils and lipids such as soybean oil, sunflower oil, castor oil, coconut oil, etc., fatty acids such as palmitic acid, stearic acid, linolenic acid, etc., alcohols such as glycerol, ethanol, etc., and organic acids such as acetic acid. These carbon sources may be used individually or in combination. Organic materials such as peptone, yeast extract, beef extract, malt extract, corn steep liquor, soybean, etc., urea, and inorganic compounds such as ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate may be used individually or in combination as nitrogen sources in the medium. Potassium dihydrogen phosphate or dipotassium hydrogen phosphate, or corresponding sodium salts may be useful as phosphorus sources. In addition, the culture medium may contain metal salts such as magnesium sulfate, iron sulfate, etc. Further, amino acids and/or vitamins may be required as essential elements. The culture medium may also contain suitable precursors. These materials may be added to a medium in a batch manner or continuous manner.
  • The culture medium may be adjusted in pH by basic compounds such as sodium hydroxide, potassium hydroxide, ammonia, etc. or acid compounds such as phosphoric acid or sulfuric acid. An antifoaming agent such as fatty acid polyglycol ester may be used to prevent the generation of bubbles during the culturing. The medium may be aerated with oxygen or oxygen-containing gas (e.g., air) to maintain an aerobic condition or with nitrogen, hydrogen or carbon dioxide gas to maintain an anaerobic condition. Culturing temperature is usually maintained at 20℃ ~ 45℃, and preferably at 30℃ ~ 35℃. Culturing is continued until the maximum amount of XMP is obtained. In this regard, a time period of from 10 to 160 hours is required.
  • The 5XMP thus produced may be secreted into the culture medium or remain within the cell. The method of producing XMP in accordance with the present invention comprises recovering XMP from the cells or the culture medium. For the recovery of XMP from cells or culture media, any method well known in the art may be utilized. Examples of such methods include filtration, anionic exchange chromatography, crystallization, and HPLC, but are not limited thereto.
  • As used herein, the term “5'-xanthosine monophosphate” is an intermediate in nucleic acid biosynthesis and is of physiological significance in animals and plants. Thus, it finds applications in a variety of fields including the food industry, the pharmaceutical industry and the medical industry. Xanthosine monophosphate are food additives used as nucleic acid-based flavor enhancers to provide the taste of mushroom particularly in synergy with MSG. XMP is an intermediate in purine metabolism, formed from IMP, forming GMP. When using the transformed microorganism in accordance with the present invention, XMP can be produced in a high yield which is found to be improved by about 6% compared to conventional microorganisms.
  • Thanks to improved malate dehydrogenase activity, the transformed corynebacteria strain of the present invention produces XMP in higher yield than do conventional microorganisms.
  • FIG. 1 is a schematic diagram showing the structure of the recombinant vector pDZ-mqo in which two copies of an mqo gene are inserted into a pDZ vector.
  • A better understanding of the present invention may be obtained through the following examples which are set forth to illustrate, but are not to be construed as limiting the present invention.
  • EXAMPLE 1: Cloning of the XMP-Producing Strain Corynebacterium ammoniagenes KCCM-10530-Derived mqo and Construction of Recombinant Vector (pDZ-mqo) for Genomic Incorporation
  • The nucleotide sequence of the mqo gene (NCBI ID_3345228) was obtained from data from the NIH GenBank. Based on the sequence, two pairs of primers (SEQ ID NOS. 1 to 4) were synthesized.
  • While the genome of Corynebacterium KCCM-10530 served as a template, PCR was conducted in the presence of the high-fidelity DNA polymerase PfuUltra™ (Stratagene) using the primers of SEQ ID NOS. 1 to 4, with 25 cycles of denaturing at 95℃ for 30 sec, annealing at 55℃ for 30 sec and extension at 68℃ for 2 min. The PCR products thus obtained were two copies of the mqo gene, each 2.1 kb long (mqo-A, mqo-B), which were amplified using two sets of SEQ ID NOS: 1 and 2, and SEQ ID NOS: 3 and 4, respectively.
  • SEQ ID NO: 1; gctctagaATCGGTCATTCCATGAACCC
  • SEQ ID NO: 2; cgcggatccCATCGATATCGCCAACTCCA
  • SEQ ID NO: 3; cgcggatccATCGGTCATTCCATGAACCC
  • SEQ ID NO: 4; gctctagaCATCGATATCGCCAACTCCA
  • After being treated with suitable restriction enzymes (mqo-A: XbaI + BamHI, mqo-B: BamHI + XbaI), the PCR products mqo-A and mqo-B were inserted into the pDZ vector which was previously treated with XbaI and shrimp alkaline phosphotase, through the three-piece junction (see Korean Patent Application No. 10-2007-94433). Finally, a recombinant pDZ-mqo vector in which two copies of the mqo gene were cloned in tandem was obtained. FIG. 1 is a schematic diagram showing the structure of the recombinant pDZ-mqo vector for incorporation into Corynebacterium genome.
  • EXAMPLE 2: Generation of an mqo-Inserted Strain
  • The pDZ-mqo vector construct was transformed into the KCCM-10530 strain and subjected to homologous recombination with the genome to insert one mqo gene copy at a position adjacent to the mqo gene on the genome. Thus, a novel XMP-producing strain, named Corynebacterium ammoniagenes KCJ-1304, which had two copies of the mqo gene on the genome thereof, was obtained. The insertion of two copies of the mqo gene in tandem was identified using PCR using a set of primers (SEQ ID NOS. 5 and 6) which targeted nucleotide sequences upstream and downstream of the two copies of the mqo gene.
  • SEQ ID NO. 5: CTTTTCGATGACGCCCAA
  • SEQ ID NO. 6: CCACTTTATCGGGTGAGACCA
  • EXAMPLE 3: Malate Dehydrogenase Activity of the mqo-Inserted Strain
  • The XMP-producing Corynebacterium ammoniagenes KCJ-1304 prepared in Example 2 was assayed for malate dehydrogenase activity as follows. The strain was inoculated into a medium containing 10g/ℓ bactopeptone, 5g/ℓ bacto-beef extract, 5g/ℓ bacto-yeast extract, 2.5g/ℓ NaCl, 50 mg/ℓ adenine, and 50 mg/ℓ guanine and incubated at 30℃ for 12 hrs until OD 10 was obtained. 10 mL of the cell culture was recovered, washed twice with buffer comprising 50 mM HEPES, 10mM potassium acetate, 10mM CaCl2 and 10mM MgCl2, and suspended in 1 mL of the same buffer. After interruption using a sonicator, the cell lysate was centrifuged. The supernatant was re-centrifuged to give a pellet which was then suspended in 100 μL of buffer. 10 μL of this suspension was used as an enzyme solution. A reaction buffer was prepared by mixing 50mM HEPES, 10mM potassium acetate and 50 μM 2,6-dichloroindolphenol (Cl2Ind). Cl2Ind was thawed and mixed just before reaction. To 980 μL of the reaction mixture were added 10 μL of 100 mM malate as a substrate and 10 μL of the enzyme solution, followed by incubation at 30℃ for 15 min with shaking. The enzyme activity was determined by measuring the concentration of reduced Cl2Ind. Cl2Ind had an absorption coefficient of 22 cm-1mM-1 at 600 nm.
  • Table 1
    Strain KCCM-10530 KCJ-1304
    Reduced Cl2Ind(μM) 15.45 20.17
  • As shown in Table 1, KCJ-1304 was observed to increase in malate dehydrogenase activity by 30.6% compared to the mother strain KCCM-10530.
  • EXAMPLE 4: XMP Production of the mqo-Inserted Strain
  • The XMP-producing strain Corynebacterium ammoniagenes KCJ-1304 prepared in Example 2 was cultured to produce XMP as follows. The mother strain Corynebacterium ammoniagenes KCCM-10530 and the mutant KCJ-1304 were inoculated into respective 14 mL tubes, each containing 3 mL of the following seed medium, and incubated at 30℃ for 20 hrs with shaking at 200 rpm. Then, the seed cultures were added in an amount of 0.4 mL to 32 mL of the following production medium (24 mL of main medium + 8 mL of medium A) in respective 250 mL corner-baffle flasks, followed by shake culturing at 30℃ and 230 rpm for 96 hrs. Thereafter, the production of 5’-XMP was quantitatively measured using HPLC. The XMP amounts produced from Corynebacterium ammogenes KCCM-10530 and KCJ-1304 are given in Table 2, below.
  • Table 2
    Strain KCCM-10530 KCJ-1304
    KCCM-10530 28.6 30.3
  • Seed Medium: glucose 30g/ℓ, peptone 15g/ℓ, yeast extract 15g/ℓ, NaCl 2.5g/ℓ, urea 3g/ℓ, adenine 150 mg/ℓ, guanine 150 mg/ℓ, pH 7.2
  • Production Medium (main): glucose 80g/ℓ, magnesium sulfate 10g/ℓ, ferrous sulfate 20 mg/ℓ, zinc sulfate 10 mg/ℓ, manganese sulfate 10 mg/ℓ, adenine 30 mg/ℓ, guanine 30 mg/ℓ, biotin 100 ㎍/ℓ, copper sulfate 1 mg/ℓ, thiamine chloride 5 mg/ℓ, calcium chloride 10 mg/ℓ, pH 7.2
  • Production Medium (medium A): monopotassium phosphate 10g/ℓ, dipotassium phosphate 10g/ℓ, urea 7g/ℓ, ammonium sulfate 5g/ℓ
  • As is apparent from the data of Table 2, KCJ-1304 was found to increase in XMP production by 1.7 g/l, corresponding to 5.9% increase, compared to the mother strain KCCM-10530.
  • Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.

Claims (8)

  1. A Corynebacteria strain, which has a malate dehydrogenase activity higher than that of a wild-type for producing 5'-xanthosine monophosphate.
  2. The Corynebacteria strain according to claim 1, wherein the malate dehydrogenase activity is improved resulting from an increase in mqo expression.
  3. A recombinant vector, having a structure shown in a cleavage map of FIG. 1.
  4. A Corynebacteria strain, transformed with the recombinant vector of claim 3.
  5. The Corynebacteria strain according to claim 4, showing an enhanced malate dehydrogenase activity.
  6. The Corynebacteria strain according to claim 4, the strain being a Corynebacterium ammoniagenes strain enhanced in 5'-xanthosine monophosphate productivity.
  7. The Corynebacteria strain according to claim 6, the strain being Corynebacterium ammoniagenes KCCM10972P.
  8. A method of producing 5'-xanthosine monophosphate, comprising culturing the Corynebacteria strain of claim 4; and obtaining 5'-xanthosine monophosphate from the culture.
EP09833645.6A 2008-12-17 2009-12-17 A corynebacteria strain having enhanced 5'-xanthosine monophosphate productivity and a method of producing 5'-xanthosine monophosphate using the same Active EP2358866B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080128847A KR101072708B1 (en) 2008-12-17 2008-12-17 A corynebacteria having enhanced 5'-xanthosine monophosphate productivity and a method of producing 5'-xanthosine monophosphate using the same
PCT/KR2009/007559 WO2010071367A2 (en) 2008-12-17 2009-12-17 A corynebacteria strain having enhanced 5'-xanthosine monophosphate productivity and a method of producing 5'-xanthosine monophosphate using the same

Publications (3)

Publication Number Publication Date
EP2358866A2 true EP2358866A2 (en) 2011-08-24
EP2358866A4 EP2358866A4 (en) 2012-08-22
EP2358866B1 EP2358866B1 (en) 2015-10-07

Family

ID=42269248

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09833645.6A Active EP2358866B1 (en) 2008-12-17 2009-12-17 A corynebacteria strain having enhanced 5'-xanthosine monophosphate productivity and a method of producing 5'-xanthosine monophosphate using the same

Country Status (8)

Country Link
US (1) US8815545B2 (en)
EP (1) EP2358866B1 (en)
JP (1) JP5553842B2 (en)
KR (1) KR101072708B1 (en)
CN (2) CN102317433B (en)
DK (1) DK2358866T3 (en)
ES (1) ES2553571T3 (en)
WO (1) WO2010071367A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101072720B1 (en) * 2008-12-17 2011-10-11 씨제이제일제당 (주) A corynebacteria having enhanced 5'-guanosine monophosphate productivity and a method of producing 5'-guanosine monophosphate using the same
KR101929158B1 (en) * 2018-06-07 2018-12-13 씨제이제일제당 (주) XMP-producing microorganism and method of producing XMP using the same
KR102273637B1 (en) * 2021-01-29 2021-07-06 씨제이제일제당 주식회사 Novel Peptidyl-dipeptidase variant and a method for producing XMP or GMP using the same
KR102258159B1 (en) * 2021-01-29 2021-05-27 씨제이제일제당 (주) Novel malate dehydrogenase variant and a method for producing L-lysine using the same
KR102288398B1 (en) * 2021-01-29 2021-08-10 씨제이제일제당 주식회사 Novel NAD(P)-dependent oxidoreductase variant and a method for producing XMP or GMP using the same
KR102572849B1 (en) * 2022-07-11 2023-08-31 대상 주식회사 Mutant microorganism of Corynebacterium genus producing L-glutamic acid and method for producing L-glutamic acid using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19912384A1 (en) 1999-03-19 2000-09-21 Degussa Process for the fermentative production of L-amino acids using coryneform bacteria
US20020028490A1 (en) 1999-03-19 2002-03-07 Douwe Molenaar Process for the production of L-amino acids by fermentation using coryneform bacteria
JP2004501651A (en) * 2000-06-23 2004-01-22 ノボザイムス アクティーゼルスカブ Methods for stable chromosomal multicopy integration of genes
DE10032350A1 (en) * 2000-07-04 2002-01-24 Degussa New coryneform bacterium in which the mdhA gene is attenuated, preferably eliminated, useful for fermentative production of L-amino acids such as L-lysine
KR100405990B1 (en) 2000-10-04 2003-11-20 김성준 Processs for Preparing Organic Germanium from Cordyceps militaris
RU2209249C2 (en) 2000-11-22 2003-07-27 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" Method for preparing xanthosine 5'-monophosphate, strain corynebacterium ammoniagenes as producer of xanthosine 5'-monophosphate (variants)
KR100402320B1 (en) 2001-01-05 2003-10-22 씨제이 주식회사 A microorganism Corynebacterium ammoniagenes NV4-82-9 being capable of producing 5'-xanthylic acid in higher yield and a producing method of 5'-xanthylic acid by using the same
DE10117816A1 (en) * 2001-04-10 2002-10-17 Degussa Improved production of L-amino acids in coryneform bacteria, useful particularly in animal nutrition, by reducing activity of malate-quinone oxidoreductase
KR20040051731A (en) * 2002-12-11 2004-06-19 씨제이 주식회사 Microorganism producing 5’-Xanthylic acid
KR100505925B1 (en) * 2002-12-11 2005-08-03 씨제이 주식회사 Microorganism producing 5’-Xanthylic acid
KR100542568B1 (en) * 2003-12-10 2006-01-11 씨제이 주식회사 Microorganisms Producing 5'-Xanthyl Acid
ZA200706659B (en) 2005-01-12 2008-10-29 Unovo Inc Method and apparatus for evacuating and sealing containers
EP3170889A1 (en) 2006-09-15 2017-05-24 CJ Cheiljedang Corporation A corynebacteria having enhanced l-lysine productivity and a method of producing l-lysine using the same
KR100789274B1 (en) * 2007-01-15 2008-01-02 씨제이 주식회사 Novel promoter nucleic acid molecules derived from Corynebacterium glutamicum, recombinant vectors comprising the promoter, host cells comprising the recombinant vector, and methods of expressing genes using the host cells
KR100957690B1 (en) 2008-01-22 2010-05-12 씨제이제일제당 (주) Microorganisms of the genus Corynebacterium with improved 5'-xanthyl acid production capacity and method of producing 5'-xanthyl acid using the same
KR101072720B1 (en) 2008-12-17 2011-10-11 씨제이제일제당 (주) A corynebacteria having enhanced 5'-guanosine monophosphate productivity and a method of producing 5'-guanosine monophosphate using the same
KR101210704B1 (en) * 2010-03-19 2012-12-10 씨제이제일제당 (주) Microorganism having enhanced 5'-xanthosine monophosphate and 5'-guanine monophosphate productivity and a method of producing 5'-xanthosine monophosphate or 5'-guanine monophosphate using the same

Also Published As

Publication number Publication date
KR20100070219A (en) 2010-06-25
JP5553842B2 (en) 2014-07-16
CN102317433A (en) 2012-01-11
WO2010071367A2 (en) 2010-06-24
DK2358866T3 (en) 2015-11-23
CN104130966A (en) 2014-11-05
ES2553571T3 (en) 2015-12-10
US20110300582A1 (en) 2011-12-08
EP2358866B1 (en) 2015-10-07
JP2012511925A (en) 2012-05-31
KR101072708B1 (en) 2011-10-11
US8815545B2 (en) 2014-08-26
WO2010071367A3 (en) 2010-11-04
CN102317433B (en) 2016-09-07
EP2358866A4 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
WO2011115439A2 (en) Microorganism with improved production of 5'-xanthosine monophosphate and 5'-guanine monophosphate, and production method of 5'-xanthosine monophosphate and 5'-guanine monophosphate using same
WO2010114245A2 (en) Microorganisms of corynebacterium with improved 5'-inosinic acid productivity, and method for producing nucleic acids using same
WO2010071367A2 (en) A corynebacteria strain having enhanced 5'-xanthosine monophosphate productivity and a method of producing 5'-xanthosine monophosphate using the same
WO2021162189A1 (en) Corynebacterium glutamicum mutant strain having improved l-glutamic acid production ability, and method for producing l-glutamic acid using same
WO2010071366A2 (en) A corynebacteria strain for enhancement of 5'-guanosine monophosphate productivity and a method of producing 5'-guanosine monophosphate using the same
KR101285945B1 (en) Corynebacterium sp. Having Improved L-lysine Production and Process for Preparing the L-lysine Employing the Same
WO2009091206A2 (en) Microorganism of genus corynebacterium capable of potentiating 5'-guanosine mono-phosphate productivity and method for producing 5'-guanosine mono-phosphate
WO2015142021A1 (en) Microorganisms having enhanced l-amino acids productivity and process for producing l-amino acids using the same
WO2012008810A2 (en) Microorganism with enhanced l-lysine productivity and method for producing l-lysine using the same
WO2023106543A1 (en) Corynebacterium glutamicum variant having improved l-lysine production ability and method for producing l-lysine by using same
WO2021201489A1 (en) Recombinant vector for transformation improving glutamine productivity, and strain employing same
WO2023063547A1 (en) Corynebacterium glutamicum variant having improved l-lysine production ability and method for producing l-lysine by using same
WO2018151347A1 (en) Microorganism having l-threonine production potential and method for producing l-threonine using same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110616

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120724

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 19/02 20060101ALI20120718BHEP

Ipc: C12N 1/20 20060101AFI20120718BHEP

Ipc: C12P 19/34 20060101ALI20120718BHEP

17Q First examination report despatched

Effective date: 20130305

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150508

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 753780

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151015

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009034100

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20151117

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2553571

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20151210

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 753780

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151007

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160107

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160208

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160108

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009034100

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151217

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

26N No opposition filed

Effective date: 20160708

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20091217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151007

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230606

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250821

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20250822

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20250820

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250821

Year of fee payment: 17

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250820

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251001

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20251010

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20260122

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20260101

Year of fee payment: 17